The most common drugs that cause drug-induced parkinsonism (DIP) are older antipsychotics like haloperidol and chlorpromazine, but the list extends well beyond psychiatric medications to include certain anti-nausea drugs, newer antipsychotics, calcium channel blockers, and even some mood stabilizers. DIP is the second most common cause of parkinsonism overall, accounting for about 12% of all parkinsonism cases in a 30-year population study.
All of these drugs share one thing in common: they interfere with dopamine signaling in the brain. Without enough dopamine activity in the movement-control circuits, the result is tremor, stiffness, and slowed movement that can look nearly identical to Parkinson’s disease.
Older (Typical) Antipsychotics
First-generation antipsychotics carry the highest risk. These drugs work by blocking dopamine receptors in the brain, which helps control psychosis but also disrupts the same pathways that coordinate movement. The specific medications in this category include haloperidol, chlorpromazine, promazine, perphenazine, fluphenazine, and pimozide.
The risk is substantial. In early studies of chlorpromazine, roughly 40% of patients developed parkinsonian symptoms. About 80% of people taking typical antipsychotics experience at least one type of movement side effect, whether that’s tremor, stiffness, restlessness, or involuntary movements. Higher doses increase the risk, but some people develop symptoms even at standard doses.
Newer (Atypical) Antipsychotics
Second-generation antipsychotics were designed to cause fewer movement side effects, and they generally do. But they are not risk-free. Risperidone, olanzapine, and quetiapine can all cause parkinsonism, particularly at higher doses or in older adults. Risperidone carries a notable risk at higher doses because it blocks dopamine receptors more strongly than other atypical antipsychotics.
A large Canadian study of older adults with dementia compared all three drugs head-to-head and found something surprising: there was no clear evidence that quetiapine, olanzapine, or risperidone differed meaningfully in their tendency to cause parkinsonism at comparable doses. Medium-dose olanzapine did show a higher incidence than low-dose risperidone, reinforcing that dose matters as much as which drug you take. The idea that certain atypical antipsychotics are “safe” for movement side effects doesn’t hold up as neatly as once thought, especially in vulnerable populations like the elderly.
Anti-Nausea Medications
This is the category that catches many people off guard. Metoclopramide (commonly prescribed for nausea, acid reflux, and gastroparesis) and prochlorperazine (used for nausea and migraines) both block dopamine receptors in the same way antipsychotics do. Because these drugs are prescribed for seemingly routine stomach or nausea problems, the connection to parkinsonism is often missed or delayed.
Metoclopramide is a particularly common culprit because it’s widely prescribed and sometimes used for months or years. The longer you take it and the higher the dose, the greater the risk. Many cases of DIP from anti-nausea drugs occur in older adults who have been on the medication for an extended period without anyone connecting their new tremor or shuffling gait to the prescription.
Calcium Channel Blockers
Two calcium channel blockers used for vertigo and migraines, cinnarizine and flunarizine, are well-established causes of drug-induced parkinsonism. These are more commonly prescribed in Europe, Asia, and Latin America than in the United States.
Their mechanism is different from antipsychotics. Rather than blocking dopamine receptors directly, cinnarizine and flunarizine interfere with how nerve cells store and release dopamine. They disrupt the tiny storage compartments inside neurons that package dopamine, reducing the amount available for signaling. Lab research found that cinnarizine cut dopamine uptake into these storage compartments by 76%, and the concentrations needed to cause this disruption fall within the range of normal therapeutic blood levels. In other words, the doses people actually take for vertigo are enough to impair dopamine storage.
Mood Stabilizers and Other Medications
Valproic acid (also sold as divalproex sodium), a medication widely used for epilepsy and bipolar disorder, can cause parkinsonism that sometimes takes years to appear. One documented case involved a patient who developed parkinsonian symptoms and cognitive decline eight years after starting the medication. The mechanism isn’t fully pinned down but likely involves effects on dopamine and other brain signaling systems. Importantly, the symptoms resolved after stopping the drug, even after such a long period of use.
Other less common causes include certain antidepressants (particularly SSRIs in some individuals), lithium, and some older blood pressure medications like reserpine, which depletes dopamine from nerve cells rather than blocking its receptors.
How DIP Differs From Parkinson’s Disease
The symptoms of drug-induced parkinsonism and Parkinson’s disease overlap heavily, which is why DIP is frequently misdiagnosed. But there are reliable patterns that separate them. DIP typically develops within days to weeks of starting a new medication or increasing a dose. Parkinson’s disease creeps in gradually over months or years with no identifiable trigger.
The physical presentation differs too. DIP usually affects both sides of the body roughly equally, particularly the upper limbs. Parkinson’s disease almost always starts on one side. The classic resting tremor that defines Parkinson’s (a hand trembling while sitting still) is rare or mild in DIP. If you notice new stiffness, slowness, or a shuffling walk that appeared on both sides around the same time you started or changed a medication, that pattern points strongly toward DIP.
Recovery After Stopping the Drug
The defining feature of DIP is that it improves once the responsible medication is removed. About two-thirds of patients recover within seven weeks of stopping the drug. Most cases resolve within six months. A smaller number of people take up to 18 months to fully recover, and some case reports describe persistent symptoms lasting nine months even when brain imaging confirmed no underlying Parkinson’s disease. This means recovery sometimes requires patience and continued monitoring well beyond the first few weeks.
For people who cannot stop the offending medication because it’s essential for their psychiatric or medical condition, switching to an alternative with less dopamine-blocking activity is the usual approach. The timeline and strategy depend on why the medication was prescribed in the first place, but the core principle stays the same: reducing the drug’s interference with dopamine signaling is what allows the movement symptoms to clear.
Who Is Most at Risk
Older adults face the highest risk of developing DIP. Aging brains have fewer dopamine-producing neurons to begin with, so even modest dopamine blockade can tip the balance into parkinsonian symptoms. Women appear to be affected more often than men in most studies. Higher doses, longer duration of use, and taking multiple dopamine-blocking medications simultaneously all increase risk. People with a family history of Parkinson’s disease or subtle pre-existing dopamine deficits may also be more susceptible, which is why some cases of DIP unmask early Parkinson’s disease that would have taken years to become apparent on its own.